Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended March 31, 2013
Announcement Date: April 24, 2013
GSK reported Q1 2013 results reflecting a strategic focus on pipeline delivery, operational restructuring, and shareholder returns. The quarter included the implementation of IAS 19 (Revised) regarding employee benefits, which impacted reported costs. The company announced a decision to divest its Lucozade and Ribena brands and plans to create a separate Global Established Products portfolio for pharmaceutical tail brands.
Key Financial Metrics
| Metric | Q1 2013 | Q1 2012 (Restated) | CER Growth % |
|---|---|---|---|
| Turnover | £6,471 million | £6,640 million | (2)% |
| Core Operating Profit | £1,925 million | £2,048 million | (11)% |
| Total Operating Profit | £1,580 million | £2,014 million | (26)% |
| Core Earnings Per Share (EPS) | 26.9p | 26.9p | (6)% |
| Total EPS | 19.9p | 26.4p | (30)% |
| Adjusted Net Cash Inflow (Operating) | £1,385 million | £1,072 million | 29% |
| Net Debt | £15,406 million | £8,876 million | N/A |
Dividend: First interim dividend declared at 18p per share (up 6% from 17p in Q1 2012).
Material Changes vs. Prior Period
- Revenue Decline: Total turnover fell 2% at constant exchange rates (CER). Excluding divestments (Vesicare and non-core OTC brands), sales grew 2%. Pharmaceuticals and Vaccines sales declined 2% (up 1% ex-divestments), while Consumer Healthcare grew 1% (up 6% ex-divestments).
- Profitability Pressure: Core operating profit margin decreased by 1.1 percentage points to 29.7%. This was driven by higher cost of sales (unwinding of manufacturing volume shortfalls) and increased SG&A, partially offset by lower R&D spend and higher royalty income.
- Regional Performance:
- US: Pharmaceuticals and Vaccines sales down 6% (up 4% excluding Vesicare). Strong growth in respiratory (+7%) and oncology (+24%) offset by generic competition to Lamictal and Duac.
- Europe: Sales down 3%, primarily due to price reductions, though an improvement on recent quarters.
- EMAP: Sales up 8%, driven by growth in Middle East/Africa and China.
- Japan: Sales down 8%, heavily impacted by a sharp decline in Cervarix sales following the conclusion of the HPV catch-up program.
- Debt Increase: Net debt rose to £15.4 billion from £14.0 billion at year-end 2012, driven by the acquisition of additional shares in the Indian consumer healthcare subsidiary (£588 million) and foreign exchange translation impacts.
Guidance, Outlook, and Risks
- 2013 Guidance: Unchanged expectations for full-year sales growth of approximately 1% (CER) and core EPS growth of 3-4% (CER).
- R&D Pipeline: Significant progress reported with positive FDA Advisory Committee recommendations for Breo Ellipta (COPD) and Priority Review granted for dolutegravir (HIV). Six key assets are now under regulatory review in the US and Europe.
- Restructuring: The "Major Change" programme is progressing, targeting annual savings of at least £1 billion by 2016. The "Operational Excellence" programme remains on track for £2.8 billion in annual savings by 2014.
- Strategic Divestments: GSK plans to divest Lucozade and Ribena to better leverage their growth potential outside Western markets. A Global Established Products portfolio will be formed for tail-end pharmaceutical brands, reported separately from January 2014.
- Risks: Ongoing legal proceedings (product liability, IP, tax) remain a contingency. The commercial environment in Europe remains challenging due to austerity measures. Currency fluctuations continue to impact reported results.
Investor Verification Checklist
- Divestment Execution: Verify the timeline and valuation realization for the proposed divestment of Lucozade and Ribena.
- Pipeline Approvals: Monitor the final FDA decision on Breo Ellipta (Action date May 12) and the approval status of dolutegravir (Action date August 17).
- Restructuring Costs vs. Savings: Track the actual delivery of the £1 billion annual savings target from the Major Change programme against the £1.5 billion total cost.
- Generic Erosion: Assess the long-term impact of generic competition on key franchises like Lamictal, Paxil, and Vesicare on future margins.
- Net Debt Trajectory: Review the company's ability to manage the increased net debt position (£15.4 billion) while maintaining the targeted £1-2 billion share repurchase program.